Advertisement
NEW YORK, April 9, 2019 /PRNewswire-PRWeb/ -- The Conference Forum, announces the keynote and speaking faculty for the 4th annual summit to be held June 20 - 21, 2019 at the Wyndham Philadelphia Historic District Hotel, Philadelphia.
Dr Drew Pardoll, world-renowned cancer researcher and immunotherapy expert and Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Professor of Oncology at Johns Hopkins University School of Medicine will be delivering the program opening keynote on Hubble's Constant for the Expanding Universe of Immunotherapy. Dr Pardoll had a hand in marking a momentous step forward in IO as he served as co-investigator on the initial clinical trials at Johns Hopkins that introduced anti-PD-1 and anti-PD-L1 antibodies for the treatment of cancer patients.
Dr Bruce Levine, an innovator in cell and gene therapy and Barbara and Edward Netter Professor in Cancer Gene Therapy, Perelman School of Medicine at the University of Pennsylvania (UPenn) opens day two with a keynote on Clinical Trials of Double Chimeric Antigen Receptor (CAR) T Cells and Engineered T Cell Combination Therapies. Dr Levine is known for creating a groundbreaking microbead technology with Dr Carl June, UPenn, that acts as an artificial substitute for dendritic cells that give T cells the signal to attack cancer cells. This technology is now the primary method used to grow activated T cells.
IO Combinations 360° introduces two new sessions for the 2019 program. The first focuses on Next Generation Cell Therapy, which features talks on NK CAR Combinations led by MD Anderson Cancer Center, Combination Strategies for CAR T Therapies presented by Janssen Oncology, and a panel addressing new opportunities and emerging approaches for cell therapy combinations. The second includes Bispecifics, which features talks on TGF Data M7824 led by EMD Serono, BiTE® Combinations led by Amgen and a panel on advancing bispecifics for combination immunotherapy.
Dr Ian McCaffery, Janssen, Dr Axel Hoos, GSK and Dr Omid Hamid, The Angeles Clinic and Research Institute are co-chairing the fourth annual IO Combinations 360° event. They will be joined by a number of distinguished speakers including new leadership with Julie Bailis, PhD, Amgen; Christopher Heery, MD, Bavarian Nordic, Mahrukh Huseni, Genentech; Laureen Ojalvo, MD, PhD, EMD Serono; Cokey Nguyen, PhD, Pfizer; Danny Wells, PhD, Parker Institute for Cancer Immunotherapy; Katy Rezvani, MD, PhD, MD Anderson Cancer Center; Willem Overwijk, PhD, Nektar Therapeutics; Joanna Horobin, Idera Pharmaceuticals; Justine Cohen, DO, Massachusetts General Hospital.
Drug development mavericks, Roy Baynes, MD, PhD, Merck and Michael Kalos, PhD, Janssen Oncology will provide updates on clinical developments including new cell therapy approaches and a deeper look at biomarkers and companion diagnostics for predicting response.
IO Combinations 360° is divided into the following plenaries with data presentations and panel discussions on Discovery and Preclinical Science, Translational Science and Emerging Biomarkers, Bispecifics, Clinical Operations and Development, Next Generation Cell Therapy, Business Developments, and Emerging Technologies.
"Due to the many advancements of IO combination therapies that are extending so many lives, we are pleased to continue presenting this conference to support the peer-to-peer learning and sharing of data" said Kate Woda, IO Combinations 360° Director.
IO Combinations 360° includes organized networking opportunities with a one-on-one partnering system to help facilitate meetings.
See full event details for IO Combinations 360°.
About The Conference Forum The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, exchange of ideas and solutions among peers, as well as providing high quality networking.
About IO Combinations 360? IO Combinations 360? is a two-day conference focused on the combinations used in immunotherapy to treat various forms of cancer. IO Combinations 360° was born from the Conference Forum's Immuno-Oncology 360 ? event as the need for a more focused program on combinations became increasingly clear with the enormous increase in overall investment.
SOURCE The Conference Forum
Advertisement
Dr Drew Pardoll, world-renowned cancer researcher and immunotherapy expert and Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Professor of Oncology at Johns Hopkins University School of Medicine will be delivering the program opening keynote on Hubble's Constant for the Expanding Universe of Immunotherapy. Dr Pardoll had a hand in marking a momentous step forward in IO as he served as co-investigator on the initial clinical trials at Johns Hopkins that introduced anti-PD-1 and anti-PD-L1 antibodies for the treatment of cancer patients.
Dr Bruce Levine, an innovator in cell and gene therapy and Barbara and Edward Netter Professor in Cancer Gene Therapy, Perelman School of Medicine at the University of Pennsylvania (UPenn) opens day two with a keynote on Clinical Trials of Double Chimeric Antigen Receptor (CAR) T Cells and Engineered T Cell Combination Therapies. Dr Levine is known for creating a groundbreaking microbead technology with Dr Carl June, UPenn, that acts as an artificial substitute for dendritic cells that give T cells the signal to attack cancer cells. This technology is now the primary method used to grow activated T cells.
IO Combinations 360° introduces two new sessions for the 2019 program. The first focuses on Next Generation Cell Therapy, which features talks on NK CAR Combinations led by MD Anderson Cancer Center, Combination Strategies for CAR T Therapies presented by Janssen Oncology, and a panel addressing new opportunities and emerging approaches for cell therapy combinations. The second includes Bispecifics, which features talks on TGF Data M7824 led by EMD Serono, BiTE® Combinations led by Amgen and a panel on advancing bispecifics for combination immunotherapy.
Dr Ian McCaffery, Janssen, Dr Axel Hoos, GSK and Dr Omid Hamid, The Angeles Clinic and Research Institute are co-chairing the fourth annual IO Combinations 360° event. They will be joined by a number of distinguished speakers including new leadership with Julie Bailis, PhD, Amgen; Christopher Heery, MD, Bavarian Nordic, Mahrukh Huseni, Genentech; Laureen Ojalvo, MD, PhD, EMD Serono; Cokey Nguyen, PhD, Pfizer; Danny Wells, PhD, Parker Institute for Cancer Immunotherapy; Katy Rezvani, MD, PhD, MD Anderson Cancer Center; Willem Overwijk, PhD, Nektar Therapeutics; Joanna Horobin, Idera Pharmaceuticals; Justine Cohen, DO, Massachusetts General Hospital.
Drug development mavericks, Roy Baynes, MD, PhD, Merck and Michael Kalos, PhD, Janssen Oncology will provide updates on clinical developments including new cell therapy approaches and a deeper look at biomarkers and companion diagnostics for predicting response.
IO Combinations 360° is divided into the following plenaries with data presentations and panel discussions on Discovery and Preclinical Science, Translational Science and Emerging Biomarkers, Bispecifics, Clinical Operations and Development, Next Generation Cell Therapy, Business Developments, and Emerging Technologies.
"Due to the many advancements of IO combination therapies that are extending so many lives, we are pleased to continue presenting this conference to support the peer-to-peer learning and sharing of data" said Kate Woda, IO Combinations 360° Director.
IO Combinations 360° includes organized networking opportunities with a one-on-one partnering system to help facilitate meetings.
See full event details for IO Combinations 360°.
About The Conference Forum The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, exchange of ideas and solutions among peers, as well as providing high quality networking.
About IO Combinations 360? IO Combinations 360? is a two-day conference focused on the combinations used in immunotherapy to treat various forms of cancer. IO Combinations 360° was born from the Conference Forum's Immuno-Oncology 360 ? event as the need for a more focused program on combinations became increasingly clear with the enormous increase in overall investment.
SOURCE The Conference Forum
